10 physician-scientists have been selected for
drug development grant to advance discoveries into the
clinic
CLEVELAND, April 16,
2024 /PRNewswire/ -- Harrington Discovery
Institute at University Hospitals in Cleveland, Ohio, today announced the 2024
class of Harrington Scholar-Innovators. The scholar awards will
support breakthrough new treatments for heart disease, autoimmune
disorders, cancer, infectious disease, inflammation, and rare
diseases using small molecule, nucleic acid, vaccine, biologic, and
gene therapies.
Harrington Discovery Institute was established in 2012 to
accelerate the development of new treatments to address major unmet
needs in medicine and society. Since its founding, Harrington has
supported 188 drugs-in-the-making, 66 institutions, 39 company
launches, 21 clinical candidates, and 15 licenses to pharma.
"Harrington Scholar-Innovators are accomplished
physician-scientists whose research demonstrates innovation,
creativity and the potential for clinical impact. In surrounding
each scholar with an experienced pharma and business development
team, we are maximizing the therapeutic potential of great
science," said Jonathan S. Stamler,
MD, President, Harrington Discovery Institute, Distinguished
University Professor and Robert S. and Sylvia K. Reitman Family
Foundation Professor of Cardiovascular Innovation at University
Hospitals and Case Western Reserve
University.
"This extraordinary group of physician-scientists constitutes
Harrington's twelfth class of Scholar-Innovators. We are excited to
help them advance their discoveries towards patients in need," said
Seth Field, MD, PhD, Director,
Physician-Scientist Programs and Investigator, Harrington Discovery
Institute and Becky Hennessy Endowed Master Clinician in Breast
Cancer Genomics.
In addition to grant funding, Harrington provides guidance and
oversight in drug and business development. Harrington
Scholar-Innovators also have the opportunity to compete for
acceleration funds up to $300,000 and
to qualify for mission-related investment funds typically up to
$2MM. Scholars have facilitated access to Harrington's
mission-aligned commercial entities including the Advent-Harrington
Impact Fund, and to its charitable partner Morgan Stanley GIFT
Cures.
The 2024 Harrington Scholar-Innovator Award recipients, their
organizations and fields of research are:
Demetrios Braddock, MD,
PhD – Yale University
DNA-Degrading Enzyme for the Treatment of Lupus
Christopher Holley, MD,
PhD – Duke University
Non-Coding RNA to Treat Atherosclerosis
Andrew Hsieh, MD – Fred
Hutchinson Cancer Research Center
Targeting mRNA Translation in Cancer
Deepak Nijhawan, MD, PhD –
University of Texas Southwestern
Medical Center
Oral Treatment of Glioblastoma
Russell Pachynski, MD –
Washington University in St.
Louis
Tumor-Targeted Therapeutic that Recruits Immune Cells
David Raleigh, MD, PhD –
University of California, San
Francisco
An Antibody Inhibiting NOTCH3+ Stem Cells in Meningioma
Julie Saba, MD, PhD –
University of California, San
Francisco
Gene Therapy for Sphingosine-1-Phosphate Lyase Insufficiency
Syndrome (SPLIS)
Carlos Subauste, MD – Case
Western Reserve University
Small Molecule Inhibitors of CD40 for the Treatment of
Inflammatory Disorders
Jordan Winter, MD –
University Hospitals Cleveland Medical Center
Targeting Wild-Type IDH1 in Pancreatic Cancer
Juliane Bubeck Wardenburg, MD,
PhD – Washington University in St.
Louis
Staphylococcus Aureus Vaccine to Provide Infant
Protection
Harrington Discovery Institute is now accepting Letters of
Intent for the 2025 Harrington Scholar-Innovator Award. The
deadline to submit a brief Letter of Intent is June 5, 2024 11:59
PM. The full application deadline, for those
invited to submit, is August 7, 2024.
Learn more and apply to the 2025 Scholar-Innovator Award at
HarringtonDiscovery.org/Scholar-Innovators.
View original
content:https://www.prnewswire.com/news-releases/harrington-discovery-institute-announces-2024-scholar-innovator-award-recipients-302118171.html
SOURCE Harrington Discovery Institute